Physician profile

Bruce E Johnson

Pulmonary Disease · Virginia Beach, VA

NPI 1619076643

$4,654.85

in general payments reported to CMS, 2019-2025

33 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $898.25 2019-2021
Astrazeneca Pharmaceuticals Lp $840.91 2019-2021
Sunovion Pharmaceuticals INC. $351.64 2019-2021
Jazz Pharmaceuticals INC. $288.36 2019-2021
Mallinckrodt Enterprises LLC $236.99 2019
Boehringer Ingelheim Pharmaceuticals, INC. $233.26 2019-2021
Mallinckrodt Hospital Products INC. $201.34 2020-2021
Advanced Respiratory, INC $162.66 2019-2021
Actelion Pharmaceuticals US, INC. $160.30 2019-2021
Genentech USA, INC. $155.91 2019
Insmed, INC. $143.10 2019-2020
Novartis Pharmaceuticals Corporation $95.66 2019-2021
Genzyme Corporation $94.16 2019-2021
Grifols USA, LLC $83.75 2019-2020
Resmed Corp $82.02 2019-2020
Show all 33 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bruce E Johnson

$4,654.85

in general payments reported 2019-2025

Years
2019-2021
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/209169/bruce-e-johnson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.